Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker
Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025.
Eli Lilly Stock Today: High Price, High Expectations
As of mid‑day on December 2, 2025, Eli Lilly and Company (NYSE: LLY) is trading around $1,057–$1,060 per share, down roughly 1–2% on the day but still close to its recent record highs. [1]
At this level:
- Lilly’s market capitalization is just under $1 trillion, after briefly crossing that mark on November 21, becoming the first drugmaker and first healthcare company ever to join the trillion‑dollar club. [2]
- The stock has climbed about one‑third over…
